In the longevity debate, “hormone balance” is often used as a synonym for “biologically younger”. Clinically, the term is only meaningful if it is linked to clearly defined axial disorders, symptomatic syndromes and patient-relevant endpoints (function, fractures, events, quality of life). The hard evidence is heterogeneous: Menopausal hormone therapy is highly effective when appropriately indicated (especially vasomotor symptoms, GSM, bone), but has been characterized for decades by GHI extrapolations and warnings; in 2025, the FDA has announced the initiation of the removal of misleading boxed warnings after a comprehensive re-evaluation. Large safety data (TRAVERSE) and current FDA label changes (including blood pressure) are available for testosterone. For DHEA (systemic) and GH as “anti-ageing”, however, the clinical evidence is significantly weaker; benefits are limited and risks and side effects are crucial in the prevention setting.
Jetzt beitreten
